FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.351,61 -2.121,94 (-3,63%)
ORMP May 2024 2.500 call
| Chiusura precedente | 0,1500 |
| Aperto | 0,1500 |
| Denaro | 0,0000 |
| Lettera | 0,5000 |
| Prezzo d'esercizio | 2,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 0,1500 - 0,1500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 178 |
GlobeNewswireScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”). Pursuant to that certain Stock Purchase Agreement entered into on Septem
- GlobeNewswire
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non
